Related Experiment Videos
Infant botulism. Epidemiological, clinical, and laboratory aspects
JAMA
|May 2, 1977
Summary
Infant botulism may result from gastrointestinal production of Clostridium botulinum toxin after organism ingestion. This infectious disease in infants presents with weakness, cranial nerve deficits, and apnea, requiring further study for public health implications.
Area of Science:
- Microbiology
- Pediatrics
- Neurology
Background:
- Clostridium botulinum is an anaerobic bacterium producing a potent neurotoxin.
- Infant botulism is a rare but serious condition affecting infants.
- Previous understanding of infant botulism sources was limited.
Purpose of the Study:
- To identify the source of Clostridium botulinum toxin in infants with botulism.
- To describe the clinical presentation and diagnostic findings in affected infants.
- To investigate the potential for in vivo toxin production.
Main Methods:
- Fecal samples analyzed for Clostridium botulinum organisms and toxin.
- Clinical histories and physical examinations documented.
- Electromyography (EMG) performed to assess neuromuscular function.
Main Results:
- Clostridium botulinum organisms and toxin detected in feces of six infants (5-20 weeks old).
- Clinical signs included constipation, weak sucking, cranial nerve deficits, weakness, and apnea.
- Characteristic EMG pattern (brief, small, abundant, motor-unit action potentials - BSAP) observed.
Conclusions:
- In vivo (gastrointestinal) production of Clostridium botulinum toxin is a likely source in these infant cases.
- This represents a newly recognized infectious disease in infants.
- Further research is needed to understand the full spectrum, incidence, and public health impact.